|
Pancreatitis
|
0.300 |
Biomarker
|
disease |
CTD_human |
Identfication of key miRNAs in pancreatitis using bioinformatics analysis of microarray data.
|
27840954 |
2016 |
|
Retinal Diseases
|
0.300 |
Biomarker
|
group |
CTD_human |
Editor's Highlight: Plasma miR-183/96/182 Cluster and miR-124 are Promising Biomarkers of Rat Retinal Toxicity.
|
27208084 |
2016 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Studies have shown that miR-182-5p can serve as a tumor oncogene or a tumor suppressive microRNA in various cancers, however, its biological role in sepsis is still uninvestigated.
|
31318050 |
2020 |
|
Carcinogenesis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
We identified miR-182-5p as a regulator of GLI2, a transcriptional regulator of the HHSP, and explored the role of the miR-182-5p/GLI2 axis in carcinogenesis and cisplatin resistance of lung adenocarcinoma (LADC).
|
31697978 |
2020 |
|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
A murine xenograft model was established to investigate the role of miR-182-5p in BC progression <i>in vivo</i>.
|
30666836 |
2019 |
|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, MET is a directly targeted gene of miR-182 in breast cancer cells.
|
29925897 |
2019 |
|
Malignant neoplasm of breast
|
0.100 |
Biomarker
|
disease |
BEFREE |
circRNA_0025202 Regulates Tamoxifen Sensitivity and Tumor Progression via Regulating the miR-182-5p/FOXO3a Axis in Breast Cancer.
|
31153828 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Upregulated in lung cancer, miRNA-182 was found to be related to cancer proliferation and chemoresistance.
|
30307642 |
2019 |
|
Malignant Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
miR-182 is a well-described oncogenic miRNA playing a crucial role in the development of many malignancies.
|
31540771 |
2019 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The ratio of cancer to benign miR-182 expression per patient was inversely associated with recurrence in a multivariate logistic regression model (odds ratio = 0.18; 95% CI, 0.03-0.89; P = 0.044).
|
30703341 |
2019 |
|
Malignant Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Besides, miR-182 mimics were transfected into MCF7 cells while miR-182 inhibitor into MDA-MB-231 cells, followed by cell proliferation and migration detection. miR-182 expression was significantly correlated with TNBC clinical indicators, such as lymph node metastasis TNM (stage III), intravascular cancer emboli and TNBC recurrence and metastasis. miR-182 expression was significantly higher in TNBC tissues than that in matched normal tissues, and was significantly higher in MDA-MB-231 cells than that in MCF7 cells. miR-182 knockdown inhibited the proliferation and migration of MDA-MB-231 cells while miR-182 overexpression markedly promoted the proliferation and migration of MCF7 cells.
|
28043147 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We demonstrated that the plasma levels of miRNA-27, miRNA-31 and miRNA-182 were significantly higher and miRNA-195 significantly lower in the whole group of LC patients and in patients with early stages of NSCLC, in comparison with healthy donors.
|
31115013 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Circ_0002483 was demonstrated to inhibit NSCLC progression in vitro and in vivo and enhanced the sensitivity of NSCLC cells to Taxol by sponging miR-182-5p to release the inhibition on GRB2, FOXO1, and FOXO3 mRNAs.
|
31844042 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
MiR-182 enhances radioresistance in non-small cell lung cancer cells by regulating FOXO3.
|
30307642 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Further study disclosed down-regulated LINC00173 was negatively corrected with miR-182-5p in NSCLC tissues.
|
31396332 |
2019 |
|
Non-Small Cell Lung Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our findings revealed that serum miR-182, 200b and 205 might serve as promising biomarkers for early detection and treatment of NSCLC.
|
30779079 |
2019 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Long noncoding RNA UCA1 enhances sensitivity to oncolytic vaccinia virus by sponging miR-18a/miR-182 and modulating the Cdc42/filopodia axis in colorectal cancer.
|
31262449 |
2019 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The effects of miR-182 silencing on transcriptomic profile were investigated using two CRC cell lines characterized by different in vivo biological behavior, the MICOL-14<sup>h-tert</sup> cell line (dormant upon transfer into immunodeficient hosts) and its tumorigenic variant, MICOL-14<sup>tum</sup>.
|
31429725 |
2019 |
|
Colorectal Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In addition, the receiver operating characteristic (ROC) and area under the curve (AUC) were used to assess the diagnostic values of the miRNAs to discriminate cancerous from non-cancerous states of the samples.The expression levels of miR-30c, miR-144, miR-375, miR-214, and miR-195 in CRC tissue were significantly downregulated (all P < .05; Paired T-Test) than that in normal adjacent tissue sample (NATS), while the expression of miR-141, miR-182, miR-183, miR-21, and miR-370 in CRC tissue were significantly upregulated (all P < .001) than that in NATS.
|
31764853 |
2019 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our research demonstrated the inhibitory function of miR-182-5p in CRC.
|
30840271 |
2019 |
|
Colorectal Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together, our findings showed that miR-182 exerted its oncogenic role in CRC by targeting DAB2IP, which may be involved in activating the PI3K/Akt/mTOR and Wnt/β-catenin pathways, shedding a novel light on the molecular mechanism of CRC tumorigenesis.
|
30974224 |
2019 |
|
Glioma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Circular RNA circ_0079593 indicates a poor prognosis and facilitates cell growth and invasion by sponging miR-182 and miR-433 in glioma.
|
31148222 |
2019 |
|
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Loss-of function together with luciferase reporter assay were used to verify the miR-182-5p modulated OSCC cells migration and metastasis was mediated by MTSS1.
|
30949866 |
2019 |
|
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
MiR-182-5p inhibited proliferation and metastasis of colorectal cancer by targeting MTDH.
|
30840271 |
2019 |
|
Neoplasm Metastasis
|
0.100 |
Biomarker
|
phenotype |
BEFREE |
Mechanistically, GAS5 functioned as a tumor suppressor in HCC metastasis through directly interacting with miR-182 and abrogating its oncogenic function in this setting.
|
30755815 |
2019 |